Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-global randomised trials of selective internal radiotherapy for metastatic colorectal cancer
Jane Wolstenholme, Francesco Fusco, Alastair M Gray, Joanna Moschandreas, Pradeep S Virdee, Sharon Love, Guy Van Hazel, Peter Gibbs, Harpreet S Wasan, Ricky A Sharma
International Journal of Cancer | WILEY | Published : 2020
Awarded by Cancer Research UK
Awarded by Bobby Moore Fund of Cancer Research UK
The FFr trial was developed by the National Cancer Research Institute Colorectal Clinical Study Group and the NIHR Clinical Research Network and equivalents in devolved nations, and was sponsored by the University of Oxford. The SIRFLOX and FOXFIRE-Global studies were sponsored by Sirtex Technology Pty Ltd. The Centre for Statistics in Medicine, Oxford provided statistical input (supported by Cancer Research UK [grant C5529/A16895]). We thank Georgie Perry and Rhona Atkin for secretarial support. This work was supported by the Bobby Moore Fund of Cancer Research UK (A8971CRUK/07/030) and Sirtex Technology Pty Ltd (FFr, FFrG and SF). A.G. is partly supported by the National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford. The FFrG and SR trials are registered at ClinicalTrials.gov, numbers: NCT01721954 and NCT00724503. The FFr trial is registered at Isrctn.com, number: ISRCTN83867919.